[Key Takeaways]
Semaglutide 2.4 mg (Wegovy) demonstrated significant liver improvement in MASH patients, even without major weight loss. This finding suggests the drug’s benefits extend beyond obesity management to broader metabolic health.
Groundbreaking Results from the ESSENCE Trial
On November 10, 2025, Novo Nordisk announced post-hoc results from its Phase 3 ESSENCE trial showing that its drug Wegovy (semaglutide 2.4 mg) significantly improved liver-injury resolution and fibrosis improvement in adult patients with Metabolic dysfunction‑associated steatohepatitis (MASH)—even among those who experienced minimal weight loss.
In the subgroup with ≤2% weight loss, 48.4% of patients receiving Wegovy achieved liver injury resolution versus 25.8% of the placebo group. Liver fibrosis improvement was also higher (27.2% vs. 18.3%). These results were presented at the 76th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C. (PR Newswire, Nov 10, 2025)
Implications for the MASH & Obesity Treatment Markets
The findings challenge the assumption that weight loss alone drives liver-disease improvement. “These data suggest that the effects … may not be solely dependent on weight loss,” said Professor Philip Newsome, co-chief investigator in the study.
For the obesity-treatment landscape, this suggests GLP-1 therapies like Wegovy could play a dual role—both as weight-management agents and as treatments for liver-disease endpoints. With MASH estimated to affect more than 250 million people globally, the commercial and clinical implications are vast. (PR Newswire, Nov 10, 2025)
Patient Impact and Global Access Considerations
Patients living with MASH—particularly those with fibrosis stage F2 or F3—stand to benefit from these results. The study showed consistent improvements across age groups, genders, and ethnicities. (PR Newswire, Nov 10, 2025)
From a global access perspective, broader use of semaglutide in MASH could reshape treatment paradigms, reduce the need for invasive biopsies, and trigger earlier intervention. The newly updated AASLD guidelines reflect this, recommending non-invasive diagnostics (like VCTE, MRE, ELF) for patient selection. (AASLD, Nov 7, 2025)
What to Watch Next
- Regulatory filings for MASH treatment with semaglutide are expected to gain traction globally—watch for approval updates, including in the U.S. and European markets.
- Reimbursement and pricing strategies will come into focus as semaglutide moves beyond obesity into liver-disease territory.
- Competitors may follow: GLP-1 and other metabolic therapies are under review for broader indications, raising questions about market competition and supply-chain readiness in this rapidly evolving space.
Editorial Note:
Having a single drug with multiple therapeutic indications can be a significant strength. However, it is crucial to verify potential side effects through rigorous clinical trials and to establish solid evidence for its expanded indications. I will continue to closely follow Wegovy’s promising therapeutic potential and future development.
If you’d like to read my previous post about Wegovy, please click the link below!
(Link: Lilly & Novo Nordisk Reach Landmark Pricing Agreement with U.S. Government on Obesity Drugs)
Leave a Reply